고혈압심장질환의 최신지견

키워드

참고문헌 (76)

1. Diez J, "Mechanisms of disease: pathologic structural remodeling is more than adaptive hypertrophy in hypertensive heart disease", Nat Clin Pract Cardiovasc Med, 2, pp.209~216 (2005)
2. Schirmer H, "Prevalence of left ventricular hypertrophy in a general population: the Tromso study", Eur Heart J, 20, pp.429~438 (1999)
3. Grossman W, "Wall stress and patterns of hypertrophy in the human left ventricle", J Clin Invest, 56, pp.56~64 (1975)
4. Verdecchia P, "Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI Study", J Am Coll Cardiol, 38, pp.1829~1835 (2001)
5. Esposito G, "Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress", Circulation, 105, pp.85~92 (2002)
6. Gosse P, "Left ventricular hypertrophy as a predictor of cardiovascular risk", J Hypertens Suppl, 23, pp.27~33 (2005)
7. Force T, "Apoptosis signal-regulating kinase", nuclear factor-kappaB: a novel signaling pathway regulates cardiomyocyte hypertrophy, 2002, pp.105, 402~404
8. Schunkert H, "Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy", N Engl J Med, 330, pp.1634~1638 (1994)
9. Berk BC, "ECM remodeling in hypertensive heart disease", J Clin Invest, 117, pp.568~575 (2007)
10. Diez J, "A translational approach to hypertensive heart disease", Hypertension, 55, pp.1~8 (2010)
11. Malmqvist K, "Relationships between left ventricular mass and the renin- angiotensin system, catecholamines, insulin and leptin", J Intern Med, 252, pp.430~439 (2002)
12. Shapiro BP, "Advanced glycation end products accumulate in vascular smooth muscle and modify vascular but not ventricular properties in elderly hypertensive canines", Circulation, 118, pp.1002~1010 (2008)
13. Ciulla MM, "Fibrosis, enzymatic and non-enzymatic cross-links in hypertensive heart disease", Cardiovasc Hematol Disord Drug Targets, 13, pp.61~73 (2011)
14. Diez J., "Towards a new paradigm about hypertensive heart disease", Med Clin North Am, 93, pp.637~645 (2009)
15. Gonzalez A, "Apoptosis in hypertensive heart disease: a clinical approach", Curr Opin Cardiol, 21, pp.288~294 (2006)
16. Wang ZV, "Autophagy in hypertensive heart disease", J Biol Chem, 285, pp.8509~8514 (2010)
17. Weber KT, "Myocardial fibrosis: functional significance and regulatory factors", Cardiovasc Res, 27, pp.341~348 (1993)
18. Verdecchia P, "Atrial fibrillation in hypertension: predictors and outcome", Hypertension, 41, pp.218~223 (2003)
19. Haider AW, "Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death", J Am Coll Cardiol, 32, pp.1454~1459 (1998)
20. Diez J, "Towards the molecular diagnosis of hypertensive heart disease?", J Hypertens, 29, pp.660~662 (2011)
21. Kuznetsova T, "Antihypertensive treatment modulates the association between the D", I ACE gene polymorphism and left ventricular hypertrophy: a meta-analysis, 2000, pp.14, 447~454
22. Kontaraki JE, "Early cardiac gene transcript levels in peripheral blood mononuclear cells in patients with untreated essential hypertension", J Hypertens, 29, pp.791~797 (2011)
23. Beaumont J, "Contribution of circulating biomarkers to unravel the role of extracellular matrix in hypertensive cardiac remodelling", J Hypertens, 30, pp.34~37 (2012)
24. Gonzalez A, "New directions in the assessment and treatment of hypertensive heart disease", Curr Opin Nephrol Hypertens, 14, pp.428~434 (2005)
25. Lopez B, "Is plasma cardiotrophin-1 a marker of hypertensive heart disease?", J Hypertens, 23, pp.625~632 (2005)
26. Martos R, "Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover", Eur J Heart Fail, 11, pp.191~197 (2009)
27. Marchesi C, "Plasma levels of matrix metalloproteinases and their inhibitors in hypertension: a systematic review and meta-analysis", J Hypertens, 30, pp.3~16 (2012)
28. Gonzalez A, "Biochemical markers of myocardial remodelling in hypertensive heart disease", Cardiovasc Res, 81, pp.509~518 (2009)
29. Ruilope LM, "Left ventricular hypertrophy and clinical outcomes in hypertensive patients", Am J Hypertens, 21, pp.500~508 (2008)
30. Nadour W, "Is left ventricular hypertrophy regression important? Does the tool used to detect it matter?", J Clin Hypertens (Greenwich), 11, pp.441~447 (2009)
31. Pewsner D, "Accuracy of electrocardiography in diagnosis of left ventricular hypertrophy in arterial hypertension: systematic review", BMJ, 335, pp.711~ (2007)
32. Ozer N, "P wave dispersion in hypertensive patients with paroxysmal atrial fibrillation", Pacing Clin Electrophysiol, 23(11), pp.1859~1862 (2000)
33. Rosen BD, "Left ventricular concentric remodeling is associated with decreased global and regional systolic function: the Multi-Ethnic Study of Atherosclerosis", Circulation, 112, pp.984~991 (2005)
34. Martos R, "Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction", Circulation, 115, pp.888~895 (2007)
35. Muller-Brunotte R, "Tissue velocity echocardiography shows early improvement in diastolic function with irbesartan and atenolol therapy in patients with hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA)", Am J Hypertens, 19, pp.927~936 (2006)
36. Saito M, "The differences in left ventricular torsional behavior between patients with hypertrophic cardiomyopathy and hypertensive heart disease", Int J Cardiol, 150, pp.301~306 (2011)
37. Tsai WC, "Postsystolic strain index is associated with delayed diastolic lengthening and diastolic dysfunction of the left ventricle in untreated hypertension", J Hypertens, 30, pp.787~793 (2012)
38. Mosterd A, "Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989", N Engl J Med, 340, pp.1221~1227 (1999)
39. Heidland UE, "Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption", Circulation, 104, pp.1477~1482 (2001)
40. Rame JE, "Development of a depressed left ventricular ejection fraction in patients with left ventricular hypertrophy and a normal ejection fraction", Am J Cardiol, 93, pp.234~237 (2004)
41. Levy D, "Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy", Circulation, 90, pp.1786~1793 (1994)
42. Gradman AH, "From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease", Prog Cardiovasc Dis, 48, pp.326~341 (2006)
43. Verdecchia P, "Prognostic significance of serial changes in left ventricular mass in essential hypertension", Circulation, 97, pp.48~54 (1998)
44. Verdecchia P, "Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial", Lancet, 374, pp.525~533 (2009)
45. Matsui Y, "Morning hypertension assessed by home monitoring is a strong predictor of concentric left ventricular hypertrophy in patients with untreated hypertension", J Clin Hypertens (Greenwich), 12, pp.776~783 (2010)
46. Ikeda T, "Morning rise in blood pressure is a predictor of left ventricular hypertrophy in treated hypertensive patients", Hypertens Res, 27, pp.939~946 (2004)
47. Mancia G, "Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation", Circulation, 95, pp.1464~1470 (1997)
48. Mathew J, "Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril", Circulation, 104, pp.1615~1621 (2001)
49. Kjeldsen SE, "Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy", JAMA, 288, pp.1491~1498 (2002)
50. Okin PM, "Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events", JAMA, 292, pp.2343~2349 (2004)
51. Wachtell K, "Change in diastolic left ventricular filling after one year of antihypertensive treatment: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study", Circulation, 105, pp.1071~1076 (2002)
52. Solomon SD, "Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomized trial", Lancet, 369, pp.2079~2087 (2007)
53. Tapp RJ, "Differential effects of antihypertensive treatment on left ventricular diastolic function: an ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) substudy", J Am Coll Cardiol, 55, pp.1875~1881 (2010)
54. Cuspidi C, "Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study", J Hypertens, 20, pp.2293~2300 (2002)
55. Galzerano D, "Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study", Am J Hypertens, 18(12), pp.1563~1569 (2005)
56. Pitt B, "Effects of eplerenone, enalapril, and eplerenone", enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study, 2003, pp.108, 1831~1838
57. Gonzalez-Fernandez RA, "Prevalence of ectopic ventricular activity after left ventricular mass regression", Am J Hypertens, 6, pp.308~313 (1993)
58. Okin PM, "Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension", JAMA, 296, pp.1242~1248 (2006)
59. Wachtell K, "Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study", Circulation, 116, pp.700~705 (2007)
60. Okin PM, "Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients", Ann Intern Med, 147, pp.311~319 (2007)
61. Klingbeil AU, "A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension", Am J Med, 115, pp.41~46 (2003)
62. Diamond JA, "Hypertensive heart disease", Hypertens Res, 28, pp.191~202 (2005)
63. Kato T, "AGEs-RAGE system mediates atrial structural remodeling in the diabetic rat", J Cardiovasc Electrophysiol, 19, pp.415~420 (2008)
64. Mitchell JA, "Early recognition and treatment of hypertensive heart disease", Curr Opin Cardiol, 20, pp.282~289 (2005)
65. Mancia G, "Prevalence of left ventricular hypertrophy in hypertensive patients without and with blood pressure control: data from the PAMELA population. Pressioni Arteriose Monitorate E Loro Associazioni", Hypertension, 39, pp.744~749 (2002)
66. Bibbins-Domingo K, "Racial differences in incident heart failure among young adults", N Engl J Med, 360, pp.1179~1190 (2009)
67. Devereux RB, "Relations of left ventricular mass to demographic and hemodynamic variables in American Indians: the Strong Heart Study", Circulation, 96, pp.1416~1423 (1997)
68. Heckbert SR, "Traditional cardiovascular risk factors in relation to left ventricular mass, volume, and systolic function by cardiac magnetic resonance imaging: the Multiethnic Study of Atherosclerosis", J Am Coll Cardiol, 48, pp.2285~2292 (2006)
69. Chung JW, "Essential hypertension and genetics", Korean Hypertension J, 13, pp.1~7 (2007)
70. Rame JE, "Corin I555(P568)allele is associated with enhanced cardiac hypertrophic response to increased systemic afterload", Hypertension, 49, pp.857~864 (2007)
71. Petretto E, "Integrated genomic approaches implicate osteoglycin(Ogn)in the regulation of left ventricular mass", Nat Genet, 40, pp.546~552 (2008)
72. Vasan RS, "Genetic variants associated with cardiac structure and function : a meta-analysis and replication of genome-wide association data", JAMA, 302, pp.168~178 (2009)
73. Devereux RB, "What is normal blood pressure? Comparison of ambulatory pressure level and variability in patients with normal or abnormal left ventricular geometry", Am J Hypertens, 6(6), pp.211~215 (1993)
74. Frey N, "Hypertrophy of the heart: a new therapeutic target?", Circulation, 109, pp.1580~1589 (2004)
75. Drazner MH, "Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health Study", J Am Coll Cardiol, 43, pp.2207~2215 (2004)
76. Basile J, "Management of global risk across the continuum of hypertensive heart disease", J Clin Hypertens (Greenwich), 8(8), pp.21~30 (2006)

관련 논문AI추천